| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
25,190,000 |
| Market
Cap: |
348.88(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.26 - $16.85 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Enanta Pharmaceuticals is a biotechnology company that discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Co.'s wholly-owned research and development programs are in virology, namely respiratory syncytial virus, hepatitis B virus, severe acute respiratory syndrome coronavirus 2, and human metapneumovirus. Two protease inhibitors developed through Co.'s Collaborative Development and License Agreement with AbbVie Inc. (AbbVie) have been clinically tested, manufactured, and commercialized by AbbVie as part of its combination regimens for hepatitis C virus. Co. also develops Farnesoid X receptor agonists for NASH.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
45,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$256,050 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
587 |
587 |
587 |
35,554 |
| Total Sell Value |
$8,195 |
$8,195 |
$8,195 |
$415,525 |
| Total People Sold |
2 |
2 |
2 |
8 |
| Total Sell Transactions |
2 |
2 |
2 |
12 |
| End Date |
2025-11-16 |
2025-08-15 |
2025-02-14 |
2024-02-15 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Luly Jay R. |
President and CEO |
• • – |
2026-02-12 |
4 |
D |
$14.25 |
$87,709 |
D/D |
(6,155) |
871,871 |
|
- |
|
| Luly Jay R. |
President and CEO |
• • – |
2026-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
878,026 |
|
- |
|
| Rottinghaus Scott T. |
Chief Medical Officer |
• – – |
2026-02-12 |
4 |
D |
$14.25 |
$48,635 |
D/D |
(3,413) |
25,254 |
|
- |
|
| Rottinghaus Scott T. |
Chief Medical Officer |
• – – |
2026-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
6,875 |
28,667 |
|
- |
|
| Luu Brendan |
Chief Business Officer |
• – – |
2026-02-12 |
4 |
D |
$14.25 |
$46,412 |
D/D |
(3,257) |
41,634 |
|
- |
|
| Luu Brendan |
Chief Business Officer |
• – – |
2026-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
6,562 |
44,891 |
|
- |
|
| Kieffer Tara Lynn |
Chief Product Strategy Officer |
• – – |
2026-02-12 |
4 |
D |
$14.25 |
$46,412 |
D/D |
(3,257) |
33,925 |
|
- |
|
| Kieffer Tara Lynn |
Chief Product Strategy Officer |
• – – |
2026-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
6,562 |
37,182 |
|
- |
|
| Or Yat Sun |
Chief Scientific Officer |
• – – |
2026-02-12 |
4 |
D |
$14.25 |
$48,635 |
D/D |
(3,413) |
374,854 |
|
- |
|
| Or Yat Sun |
Chief Scientific Officer |
• – – |
2026-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
6,875 |
378,267 |
|
- |
|
| Kowalsky Matthew Paul |
Chief Legal Officer |
• – – |
2026-02-12 |
4 |
D |
$14.25 |
$27,104 |
D/D |
(1,902) |
3,591 |
|
- |
|
| Kowalsky Matthew Paul |
Chief Legal Officer |
• – – |
2026-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,493 |
5,493 |
|
- |
|
| Trout Harry R. Iii |
See Remarks |
• – – |
2025-12-02 |
4 |
S |
$13.96 |
$5,305 |
D/D |
(380) |
16,890 |
|
1% |
|
| Capps Kathleen S. |
See Remarks |
• – – |
2025-12-02 |
4 |
S |
$13.96 |
$2,890 |
D/D |
(207) |
8,700 |
|
1% |
|
| Trout Harry R. Iii |
See Remarks |
• – – |
2025-12-01 |
4 |
D |
$14.12 |
$1,483 |
D/D |
(105) |
17,270 |
|
- |
|
| Luly Jay R. |
President and CEO |
• • – |
2025-12-01 |
4 |
D |
$14.12 |
$26,616 |
D/D |
(1,885) |
862,769 |
|
- |
|
| Capps Kathleen S. |
See Remarks |
• – – |
2025-12-01 |
4 |
D |
$14.12 |
$1,200 |
D/D |
(85) |
8,907 |
|
- |
|
| Luu Brendan |
Chief Business Officer |
• – – |
2025-12-01 |
4 |
D |
$14.12 |
$7,032 |
D/D |
(498) |
39,723 |
|
- |
|
| Or Yat Sun |
Chief Scientific Officer |
• – – |
2025-12-01 |
4 |
D |
$14.12 |
$10,632 |
D/D |
(753) |
373,782 |
|
- |
|
| Kieffer Tara Lynn |
Chief Product Strategy Officer |
• – – |
2025-12-01 |
4 |
D |
$14.12 |
$10,632 |
D/D |
(753) |
32,726 |
|
- |
|
| Capps Kathleen S. |
See Remarks |
• – – |
2025-11-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,163 |
8,992 |
|
- |
|
| Trout Harry R. Iii |
See Remarks |
• – – |
2025-11-25 |
4 |
A |
$0.00 |
$0 |
D/D |
6,463 |
17,375 |
|
- |
|
| Capps Kathleen S. |
See RemarksOfficer |
• – – |
2025-08-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,829 |
|
61% |
|
| Rottinghaus Scott T. |
Chief Medical Officer |
• – – |
2025-08-08 |
4 |
D |
$6.99 |
$15,497 |
D/D |
(2,217) |
22,590 |
|
- |
|
| Mellett Paul J |
Chief Fin. & Admin Officer |
• – – |
2025-02-12 |
4 |
D |
$5.59 |
$18,592 |
D/D |
(3,326) |
95,884 |
|
- |
|
309 Records found
|
|
Page 1 of 13 |
|
|
0.01 (0.07%) 
